AUSTIN, Texas, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Mati Therapeutics Inc. ("Mati") today announced the initiation of a Phase II trial of its L-PPDS drug delivery system in patients with ocular hypertension or primary open angle glaucoma. The study will be a U.S. based, randomized, multi-center trial of approximately 100 patients treated with L-PPDS or timolol eye drops for up to 14 weeks. The primary end point for the comparative treatments will be change from baseline in intraocular pressure (IOP). A number of secondary endpoints will also be evaluated.
Help employers find you! Check out all the jobs and post your resume.
